The core differentiator lies in a defined panel of four critical markers: Classic Hodgkin Lymphoma (cHL) and Nodular Lymphocytic-Predominant Hodgkin Lymphoma (NLPHL) exhibit mutually exclusive immunophenotypes. To formulate an IHC or antibody assay panel that reliably separates them, you must target CD30, CD15, CD20, and CD19. Hodgkin and Reed–Sternberg (RS) cells in cHL are consistently CD30-positive and ~80% CD15-positive, with weak or absent B-cell markers (CD20/CD19). In sharp contrast, the malignant lymphocyte-predominant cells of NLPHL show strong CD20 and CD19 expression but rarely express CD30 or CD15. Pairing these four high-affinity antibodies creates the diagnostic cornerstone.
Distinguishing cHL from NLPHL hinges on an antibody panel that interrogates activation and B-lineage markers simultaneously. Classic Hodgkin RS cells are CD30+ and usually CD15+ while being B-cell-marker-poor; NLPHL tumor cells are CD20+/CD19+ and lack CD30 and CD15. This selective combination – CD30, CD15, CD20, CD19 – delivers the highest specificity for routine histopathological subgrouping.
The Immunophenotypic Divide
Understanding why these marker combinations work requires a brief look at the target cells’ biology. The immunostaining pattern not only defines the lineage but also reveals the underlying disease mechanism, helping assay developers select robust reagents.
The Signature of Classic Hodgkin Lymphoma
cHL’s neoplastic RS cells are derived from crippled germinal-center B cells that have largely lost their B-cell program. Their diagnostic hallmark is near-universal CD30 expression. The tumor necrosis factor receptor CD30 is a reliable activation marker that lights up the large, multinucleated RS cells in all classical subtypes—nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.
CD15 appears on roughly 80% of cHL cases. Although not 100% sensitive, its presence adds critical diagnostic weight when combined with CD30. The classic profile reads: CD30+, CD15+ (or a subset CD30+, CD15−), with dim or completely absent CD20 and CD19. A weak CD20 signal may be seen in a minority of cHL, but strong, uniform B-cell marker expression points away from a classical diagnosis.
The Distinct Profile of NLPHL
NLPHL arises from a functional germinal-center B cell that retains its B-cell identity. The large, lobulated “popcorn” cells—lymphocyte-predominant (LP) cells—constitutively express pan-B-cell antigens CD20 and CD19 at high intensity.
These LP cells are negative for CD30 and negative for CD15, reflecting a fundamentally different pathway of malignant transformation. An antibody panel missing B-cell markers would blur the distinction; conversely, without CD30 and CD15, an Epstein-Barr virus-related or other lymphoid proliferation could be mistaken for cHL.
Building a High-Confidence IHC Panel
Designing an IVD-grade panel demands more than just marker selection. Antibody affinity, clone specificity, and the interplay of staining patterns all influence interobserver reproducibility.
Core Reagents: The Four-Marker Minimum
A minimal panel for differential diagnosis must include:
- Anti-CD30 (e.g., Ber-H2 clone): Strong membranous and Golgi staining of RS cells.
- Anti-CD15 (e.g., Carb-3 or MMA): Membranous and parameter dot-like positivity in cHL.
- Anti-CD20 (e.g., L26): Robust pan-B-cell marker; absent or faint in cHL, intense in NLPHL.
- Anti-CD19 (optional but valuable): Adds a second B-cell axis that reinforces lineage assignment when CD20 alone is ambiguous.
Including CD19 alongside CD20 guards against rare CD20-downregulated NLPHL and provides redundant evidence of B-cell derivation.
Interpreting Multiplexed Staining Results
When scoring, follow a simple decision tree:
| Marker | Classic HL (RS cells) | NLPHL (LP cells) |
|---|---|---|
| CD30 | Positive | Negative (rare weak positivity) |
| CD15 | Often positive | Negative |
| CD20 | Negative/weak | Strong positive |
| CD19 | Negative/weak | Strong positive |
A dual-positive CD30/CD15 profile with minimal B-cell signal seals a cHL diagnosis. A CD20/CD19-bright profile with no CD30 or CD15 strongly favors NLPHL.
Understanding the Trade‑offs
No marker is perfect. Recognizing the limitations of each target ensures panels are designed with built-in interpretive safeguards.
CD15 Is Variable in cHL
CD15 positivity varies by fixation, clone, and tissue processing. Approximately 20% of cHL cases are CD15-negative. A CD30+/CD15− result is not diagnostic proof of NLPHL. Morphology and B-cell marker status must be weighed together. The panel should never discard cHL based on a negative CD15 alone.
Residual B‑Cell Marker Expression in cHL
Some RS cells retain faint CD20 or CD19 expression. If only B-cell markers are assessed without CD30, a weak signal might be misinterpreted as NLPHL. Always combine activation markers with B-lineage markers to resolve ambiguity. High-affinity antibodies and optimized antigen retrieval help distinguish truly weak staining from background.
Coincidental EBV and Other Lymphomas
cHL subtypes are often EBV-positive, which can upregulate certain antigens. While EBV testing is adjunct, your core IHC panel should be unambiguous enough to separate architecture-driven doubts. Adding an EBV-LMP1 antibody is a common extension but not part of the baseline differential panel.
How to Apply This to Your Assay Development Project
Your panel configuration will depend on your intended diagnostic setting and regulatory pathway. Use these goal-oriented recommendations to finalize your antibody selection.
- If your primary focus is maximum diagnostic sensitivity for cHL screening: Prioritize high-affinity anti-CD30 and anti-CD15 clones with validated performance on FFPE tissue. Accept that CD15-negative cases may require morphological correlation, and build interpretive guidelines around the CD30+/CD20− rule.
- If your primary focus is definitively ruling in NLPHL: Ensure the panel includes two B-cell markers (CD20 and CD19) with demonstrated linear staining. Confirm that CD30 negativity is preserved across your chosen tissue controls, as weak ectopic expression can occasionally occur.
- If your primary focus is a single comprehensive IVD panel for routine histopathology: Use a five-antibody core (CD30, CD15, CD20, CD19, plus a control like PAX5 or Oct-2 to strengthen B-cell identification). Design the kit with pre-diluted reagents, standardized antigen retrieval, and a clear scoring algorithm that stops at the four-marker decision point.
- If your primary focus is entering markets where cost or regulatory burden limits panel size: The most compact yet discriminating combination is CD30, CD15, and CD20. Loss of CD19 slightly reduces B-lineage confirmation but remains diagnostically effective when paired with morphological review.
Selecting the right biomarker targets is a strategic decision that directly affects patient stratification and therapy. Build your panel around the non-overlapping immunological signatures of CD30/CD15 positivity versus CD20/CD19 positivity, and you will deliver a differential assay that pathologists trust.
Summary Table:
| Biomarker Target | Diagnostic Function | Classic Hodgkin Lymphoma (RS Cells) | Nodular Lymphocytic-Predominant HL (LP Cells) |
|---|---|---|---|
| CD30 | Activation Marker | Positive (~100%) | Negative (Rare weak) |
| CD15 | Activation / Granulocytic Marker | Positive (~80%) | Negative |
| CD20 | Lineage Pan-B-Cell Marker | Negative or Faint | Strong Positive |
| CD19 | Lineage Pan-B-Cell Marker | Negative or Faint | Strong Positive |
Accelerate Your Lymphoma Diagnostic Assay Development
Building high-specificity IHC panels requires reliable, validated antibodies and expert formulation support. CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and assay consulting—supporting your development path from initial concept to clinic.
Whether you need optimized monoclonal antibodies for CD30, CD15, CD20, or CD19, our team is ready to assist. Contact CamelBio today to discuss your assay requirements.